Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.

Current medical research and opinion - 1 Dec 2022

Leslie Lori A, Gangan Nilesh, Tan Hiangkiat, Huang Qing

Abstract excerpt

OBJECTIVES: To evaluate the trend in cytogenetic/molecular testing rate in chronic lymphocytic leukemia (CLL) and assess the clinical and economic burden of first-line (1 L) treatment with chemoimmunotherapy (CIT) by risk status. METHODS: This retrospective cohort study identified patients with CLL from a U.S. managed care population. Medical records were obtained for eligible patients who initiated 1 L CIT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 36205521
DOI: 10.1080/03007995.2022.2133468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.PMID 36205521Read ↗

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.Semantic proximity Read ↗

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.Semantic proximity Read ↗

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.Semantic proximity Read ↗

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?Semantic proximity Read ↗

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read ↗

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read ↗

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Chronic lymphocytic leukemia in Oman: real-world outcomes, molecular testing gaps, and access to targeted therapy in a low- incidence settingSemantic proximity Read ↗

Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.